At Rezq Bio, we work to offer hope to those on the lonely journey of chronic autoimmune disease.

Rezq Bio is an early stage biotech company that seeks to cure Type 1 Diabetes (T1D) and other localized autoimmune conditions. Our lead asset is a Phase 1B/2A ready autologous dendritic cell therapy that treats T1D.

T1D is a chronic autoimmune condition caused by the gradual destruction of insulin producing cells within the pancreas resulting in uncontrolled blood sugar.
•	No approved therapies exist that reverse onset or delay progression
•	Daily, lifelong insulin supplementation does not prevent complications such as heart disease, nephropathy, blindness, foot amputations, etc.

There are approximately 1.6m individuals with Type I Diabetes in the United States and 18m worldwide. 
•	64k newly diagnosed (“Early Onset”) each year and growing. 
•	$16bn in associated medical costs and lost income annually

As a platform, we believe our antisense (ASO) technology can be applied to other localized autoimmune conditions such as Colitis (IND ready), Multiple Sclerosis and Autoimmune Polyneuropathy.

Looking forward, we have also delivered microspheres loaded with ASOs as well as RA+TGF-B with success preclinically. This provides an inert, off-the-shelf delivery mechanism that does not require reprogramming one's dendritic cells externally.

Rezq Bio

Org chart

Teams

Offices